BACKGROUND: We performed serological and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in north-central Italy and a surveillance program for human herpes virus 8 (HHV8) infection after transplant, aiming to establish an optimal management of HHV8 infection in SOT recipients. METHODS: For pretransplant HHV8 screening in both donors and recipients, 6 serological (4 indirect immunofluorescent assays (IFA) and 2 enzyme-linked immunosorbent assays (ELISA) - both HHV8 lytic and latent antigen-based) and 2 molecular assays were used. A reference standard to identify HHV8-positive patients was defined by at least 2 positive assays. All transplant patients at risk to develop HHV8-related disease underwent virological posttransplant monitoring by quantitative real-time PCR assay. RESULTS: HHV8 seroprevalence was 4% (10/249) in donors and 18% (93/517) in organ recipients. The best performance was obtained by 2 lytic antigen-based IFAs that showed almost perfect agreement to the reference standard (0.943 and 0.931 Cohen’s kappa). HHV8-DNA was detected in 6.8% and 2.9% of HHV8-seropositive donor samples by in-house nested PCR and quantitative real-time PCR assays, respectively. After transplant, 3 out of 12 (25%) HHV8-mismatch patients (seropositive donor/seronegative recipient) developed a primary infection, 1 of whom developed a lethal nonmalignant illness. Two out of 93 HHV8-seropositive recipients (2.1%) had viral replication in posttransplant period, 1 of whom developed Kaposi’s sarcoma. CONCLUSIONS: Serological assays, specifically lytic IFAs, were the best methodological approach to identify HHV8-infected SOT donors and recipients. A very low incidence (1.9%) of posttransplant HHV8-related disease was observed.

Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation / Chiereghin, Angela; Barozzi, Patrizia; Petrisli, Evangelia; Piccirilli, Giulia; Gabrielli, Liliana; Riva, Giovanni; Potenza, Leonardo; Cappelli, Gianni; de Ruvo, Nicola; Libri, Irene; Maggiore, Umberto; Morelli, Maria Cristina; Potena, Luciano; Todeschini, Paola; Gibertoni, Dino; Labanti, Manuel; Sangiorgi, Gabriela; la Manna, Gaetano; Pinna, Antonio Daniele; Luppi, Mario; Lazzarotto, Tiziana. - In: TRANSPLANTATION. - ISSN 0041-1337. - 101:8(2017), pp. 1935-1944. [10.1097/TP.0000000000001740]

Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation

BAROZZI, Patrizia;RIVA, Giovanni;POTENZA, Leonardo;CAPPELLI, Gianni;LUPPI, Mario;
2017

Abstract

BACKGROUND: We performed serological and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in north-central Italy and a surveillance program for human herpes virus 8 (HHV8) infection after transplant, aiming to establish an optimal management of HHV8 infection in SOT recipients. METHODS: For pretransplant HHV8 screening in both donors and recipients, 6 serological (4 indirect immunofluorescent assays (IFA) and 2 enzyme-linked immunosorbent assays (ELISA) - both HHV8 lytic and latent antigen-based) and 2 molecular assays were used. A reference standard to identify HHV8-positive patients was defined by at least 2 positive assays. All transplant patients at risk to develop HHV8-related disease underwent virological posttransplant monitoring by quantitative real-time PCR assay. RESULTS: HHV8 seroprevalence was 4% (10/249) in donors and 18% (93/517) in organ recipients. The best performance was obtained by 2 lytic antigen-based IFAs that showed almost perfect agreement to the reference standard (0.943 and 0.931 Cohen’s kappa). HHV8-DNA was detected in 6.8% and 2.9% of HHV8-seropositive donor samples by in-house nested PCR and quantitative real-time PCR assays, respectively. After transplant, 3 out of 12 (25%) HHV8-mismatch patients (seropositive donor/seronegative recipient) developed a primary infection, 1 of whom developed a lethal nonmalignant illness. Two out of 93 HHV8-seropositive recipients (2.1%) had viral replication in posttransplant period, 1 of whom developed Kaposi’s sarcoma. CONCLUSIONS: Serological assays, specifically lytic IFAs, were the best methodological approach to identify HHV8-infected SOT donors and recipients. A very low incidence (1.9%) of posttransplant HHV8-related disease was observed.
2017
ago-2017
101
8
1935
1944
Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation / Chiereghin, Angela; Barozzi, Patrizia; Petrisli, Evangelia; Piccirilli, Giulia; Gabrielli, Liliana; Riva, Giovanni; Potenza, Leonardo; Cappelli, Gianni; de Ruvo, Nicola; Libri, Irene; Maggiore, Umberto; Morelli, Maria Cristina; Potena, Luciano; Todeschini, Paola; Gibertoni, Dino; Labanti, Manuel; Sangiorgi, Gabriela; la Manna, Gaetano; Pinna, Antonio Daniele; Luppi, Mario; Lazzarotto, Tiziana. - In: TRANSPLANTATION. - ISSN 0041-1337. - 101:8(2017), pp. 1935-1944. [10.1097/TP.0000000000001740]
Chiereghin, Angela; Barozzi, Patrizia; Petrisli, Evangelia; Piccirilli, Giulia; Gabrielli, Liliana; Riva, Giovanni; Potenza, Leonardo; Cappelli, Giann...espandi
File in questo prodotto:
File Dimensione Formato  
Multicenter_Prospective_Study_for_Laboratory.36.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 304.47 kB
Formato Adobe PDF
304.47 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
TP.0000000000001740.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 1.81 MB
Formato Adobe PDF
1.81 MB Adobe PDF Visualizza/Apri
Manuscript_HHV8 Chiereghin A_ Sept 2016.pdf

Open Access dal 01/10/2018

Tipologia: Versione originale dell'autore proposta per la pubblicazione
Dimensione 164.98 kB
Formato Adobe PDF
164.98 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1154438
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 30
social impact